Objective:To access the level of knowledge,perceptions,and practice towards adverse events following immunization(AEFI)surveillance among vaccination workers in Zhejiang province,China.Methods:This was a cross-section...Objective:To access the level of knowledge,perceptions,and practice towards adverse events following immunization(AEFI)surveillance among vaccination workers in Zhejiang province,China.Methods:This was a cross-sectional survey involving 768 vaccination workers.Data were collected using self-administered questionnaires and analyzed by using SAS 9.3 software.Knowledge,perceptions,and practice on AEFI surveillance were summarized using frequency tables.The mean±SD value was used as the cut-off for defining good(values≥mean)and poor(values<mean)knowledge,perceptions or practice.Binary logistic regression analysis was used to determine sociodemographic variables associated with knowledge,perceptions,and practice towards AEFI.Results:The proportions of good knowledge,perceptions and practice on AEFI surveillance were 78.13%,57.81%and 66.15%,respectively.Having a higher education background,longer years of experience,previous training on AEFI and≥30 years of age were factors associated with good knowledge,perceptions and practice on AEFI surveillance among vaccination workers.Conclusions:Over half of the respondents had good knowledge,perceptions and practice on AEFI surveillance work.Interventions on improving the vaccination workers’knowledge,perceptions and practice on AEFI surveillance should be considered in order to develop a more effective surveillance system.展开更多
目的分析2019—2022年湖北省狂犬病疫苗疑似预防接种异常反应(Adverse events following immunization,AEFI)监测情况,评价相关疫苗安全性。方法通过“中国疾病预防控制信息系统”和“湖北省免疫规划信息系统”收集2019—2022年湖北省...目的分析2019—2022年湖北省狂犬病疫苗疑似预防接种异常反应(Adverse events following immunization,AEFI)监测情况,评价相关疫苗安全性。方法通过“中国疾病预防控制信息系统”和“湖北省免疫规划信息系统”收集2019—2022年湖北省狂犬病疫苗接种后AEFI个案信息以及狂犬病疫苗接种情况,描述性分析AEFI发生特征和报告发生率。结果2019—2022年湖北省共报告狂犬病疫苗AEFI个案2308例,年均报告发生率为22.00/10万剂;不同年份报告发生率差异有统计学意义(χ^(2)=452.92,P<0.01)。所有AEFI个案中,一般反应、异常反应分别占96.23%、3.16%;严重AEFI、非严重AEFI报告发生率分别为0.14/10万剂、21.86/10万剂。各市(州)均有AEFI报告(仅2021年鄂州市为零报告),报告总例数居前3位的分别是荆州市、宜昌市和襄阳市。报告的AEFI中,男、女性别比为1.02∶1;2~6岁儿童占47.44%;第2、3季度报告例数较多,占比分别为35.79%、32.63%。96.92%的AEFI个案接种后至发生AEFI时间间隔≤1 d。不同制作工艺类型狂犬病疫苗AEFI报告发生率差异有统计学意义(χ^(2)=238.92,P<0.01)。冻干狂犬病疫苗(Vero细胞)的AEFI报告发生率高于其他3种狂犬病疫苗。结论2019—2022年湖北省狂犬病疫苗AEFI报告发生率呈波动下降,报告的AEFI以一般反应为主,非严重AEFI为罕见,严重AEFI为十分罕见,安全性良好。展开更多
Objective:Analyze the relationship between inoculating one case of the COVID-19 inactivated vaccine(Vero cell)and immune thrombocytopenic purpura to provide a reference for the standardized handling of adverse events ...Objective:Analyze the relationship between inoculating one case of the COVID-19 inactivated vaccine(Vero cell)and immune thrombocytopenic purpura to provide a reference for the standardized handling of adverse events following immunization.Methods:According to the"National Monitoring Program for Suspected Adverse Reactions to Vaccinations,"an on-site investigation,data collection and analysis,expert group diagnosis,and medical association assessment were conducted on a case of immune thrombocytopenic purpura in District A of Chongqing after vaccination with the inactivated COVID-19 vaccine.The assessment report was delivered to the three relevant parties,the case was reviewed,and the experience was summarized.Results:The investigation and diagnosis by the district-level vaccination abnormal reaction expert group concluded that the disease that occurred after vaccination with the COVID-19 inactivated vaccine was secondary immune thrombocytopenic purpura,an abnormal reaction to the vaccination.The medical damage was classified as Level II Grade B.The vaccine production enterprise raised objections to this conclusion.After re-assessment by the municipal-level medical association,the conclusion was consistent with that of the district-level medical association.The vaccine production enterprise did not raise any further objections.Conclusion:Through active collaboration among district and municipal-level medical associations,disease control institutions,and vaccination units,the recipients have been promptly and effectively treated,providing financial support for their subsequent treatment and safeguarding their rights.The investigation and disposal procedures for adverse events following immunization in Chongqing are clear,and the mechanism is sound.It is necessary to continue strengthening the monitoring of adverse events following immunization according to the existing plan and to ensure timely and standardized handling.Simultaneously,it is crucial to strengthen vaccine management and vaccination management.展开更多
目的分析深圳市南山区2005—2022年疑似预防接种异常反应(adverse events following immunization,AEFI)发生的流行病学特征,评价AEFI监测工作开展运转情况,评估疫苗的安全性。方法通过疑似预防接种异常反应信息管理系统收集整理深圳市...目的分析深圳市南山区2005—2022年疑似预防接种异常反应(adverse events following immunization,AEFI)发生的流行病学特征,评价AEFI监测工作开展运转情况,评估疫苗的安全性。方法通过疑似预防接种异常反应信息管理系统收集整理深圳市南山区2005—2022年监测个案数据,采用描述性方法进行流行病学分析。结果2005—2022年深圳市南山区共报告疑似预防接种异常反应病例1748例,报告发生率为9.20/10万剂。其中一般反应1411例(80.72%)、异常反应277例(15.85%)、偶合症60例(3.43%)。其中≤1岁635例占36.33%,男女性别比为1.33∶1,5月份(213例,占12.19%)报告病例最多。结论深圳市南山区疑似预防接种异常反应监测系统运转良好,但需加强接种单位相关工作人员业务培训、督导,提高监测敏感性。展开更多
目的分析2015—2019年石嘴山市免疫规划疫苗疑似预防接种异常反应(adverse events following immunization,AEFI)发生特征,评价预防接种的安全性和AEFI监测质量。方法通过中国免疫规划信息管理系统,收集石嘴山市2015—2019年免疫规划疫...目的分析2015—2019年石嘴山市免疫规划疫苗疑似预防接种异常反应(adverse events following immunization,AEFI)发生特征,评价预防接种的安全性和AEFI监测质量。方法通过中国免疫规划信息管理系统,收集石嘴山市2015—2019年免疫规划疫苗的AEFI个案和接种数据,采用描述流行病学方法对监测数据进行统计分析。结果2015—2019年,石嘴山市共报告AEFI 584例,报告发生率为66.51/10万剂,其中一般反应报告发生率为65.37/10万剂,以发热、局部红肿、局部硬结为主;异常反应报告发生率为0.91/10万剂。AEFI的发生年龄主要为<1岁组,男女性别比为1.20∶1。AEFI发生时间主要集中在第二、三季度,接种后<1 d发生的占62.33%。结论2015—2019年,石嘴山市AEFI以一般反应为主,需进一步提高AEFI监测敏感性,并加强对小年龄组儿童接种后24 h内的AEFI监测。展开更多
目的分析铜陵市疑似预防接种异常反应(adverse events following immunization,AEFI)的分布情况,评价AEFI监测工作开展情况,为预防接种的安全实施提供依据。方法通过中国疾病预防控制信息系统国家免疫规划信息系统收集2017—2021年铜陵...目的分析铜陵市疑似预防接种异常反应(adverse events following immunization,AEFI)的分布情况,评价AEFI监测工作开展情况,为预防接种的安全实施提供依据。方法通过中国疾病预防控制信息系统国家免疫规划信息系统收集2017—2021年铜陵市报告的AEFI个案数据,采用描述流行病学方法对AEFI个案发生的时间和人群特征以及不同疫苗的AEFI发生情况等进行分析。结果2017—2021年铜陵市共接种疫苗1711172剂次,报告AEFI个案937例,年均报告发生率为54.76/10万剂次;其中一般反应810例(占86.45%),异常反应125例(占13.34%),偶合症2例(占0.21%)。AEFI个案报告主要集中在3—8月(708例,占75.56%)。男女报告个案数分别为492例和445例,性别比为1.11:1;年龄分布上以2岁以下婴幼儿为主(696例,占74.28%)。报告发生率居前三位的疫苗分别为冻干流感减毒活疫苗(鼻喷)(250.94/10万剂次)、DTap-Hib四联疫苗(219.22/10万剂次)、13价肺炎疫苗(170.16/10万剂次)。75.35%的AEFI发生在接种后24 h内,所有个案均已好转或痊愈。结论铜陵市疫苗安全性总体较好,2岁以下婴幼儿是AEFI发生的重点人群。展开更多
Objective:To compare the reporting pattern of hearing loss and tinnitus across different vaccines brands used in Malaysia(BNT162b2,CoronaVac,ChAdOx1,Ad5.CoV2-S and BBIBP-CorV).Methods:This retrospective study included...Objective:To compare the reporting pattern of hearing loss and tinnitus across different vaccines brands used in Malaysia(BNT162b2,CoronaVac,ChAdOx1,Ad5.CoV2-S and BBIBP-CorV).Methods:This retrospective study included all reports of hearing loss and tinnitus occurring after COVID-19 vaccination that were received in the national pharmacovigilance database,QUEST,from February 24,2021 through July 31,2022.Reports given causality consistent or indeterminate were included.Results:There were 21 cases of hearing loss,with overall reporting rate of 0.29 cases per million doses.The rate was similar across BNT162b2,CoronaVac and ChAdOx1.For tinnitus,35 cases were reported,with the overall reporting rate of 0.49 cases per million doses,and the highest rate was reported for ChAdOx1.For both events,most cases aged 30 to 49 years.No gender disparity was observed.Both events were mainly reported to have occurred after the primary doses,with a median time-to-onset of two days.There were no statistically significant differences in the reporting patterns for both events across BNT162b2,CoronaVac and ChAdOx1 by age group,gender,race,and dose number.Conclusions:Despite the low reporting rates and insufficient evidence to confirm its relationship,hearing loss and tinnitus following vaccinations should not be ignored due to its disabling potential and impact on one’s quality of life.Continual reporting is encouraged for better signal characterization in the future.展开更多
基金funded by medical and health science and technology project of Zhejiang province (Grant number:2023KY633)
文摘Objective:To access the level of knowledge,perceptions,and practice towards adverse events following immunization(AEFI)surveillance among vaccination workers in Zhejiang province,China.Methods:This was a cross-sectional survey involving 768 vaccination workers.Data were collected using self-administered questionnaires and analyzed by using SAS 9.3 software.Knowledge,perceptions,and practice on AEFI surveillance were summarized using frequency tables.The mean±SD value was used as the cut-off for defining good(values≥mean)and poor(values<mean)knowledge,perceptions or practice.Binary logistic regression analysis was used to determine sociodemographic variables associated with knowledge,perceptions,and practice towards AEFI.Results:The proportions of good knowledge,perceptions and practice on AEFI surveillance were 78.13%,57.81%and 66.15%,respectively.Having a higher education background,longer years of experience,previous training on AEFI and≥30 years of age were factors associated with good knowledge,perceptions and practice on AEFI surveillance among vaccination workers.Conclusions:Over half of the respondents had good knowledge,perceptions and practice on AEFI surveillance work.Interventions on improving the vaccination workers’knowledge,perceptions and practice on AEFI surveillance should be considered in order to develop a more effective surveillance system.
文摘目的分析2019—2022年湖北省狂犬病疫苗疑似预防接种异常反应(Adverse events following immunization,AEFI)监测情况,评价相关疫苗安全性。方法通过“中国疾病预防控制信息系统”和“湖北省免疫规划信息系统”收集2019—2022年湖北省狂犬病疫苗接种后AEFI个案信息以及狂犬病疫苗接种情况,描述性分析AEFI发生特征和报告发生率。结果2019—2022年湖北省共报告狂犬病疫苗AEFI个案2308例,年均报告发生率为22.00/10万剂;不同年份报告发生率差异有统计学意义(χ^(2)=452.92,P<0.01)。所有AEFI个案中,一般反应、异常反应分别占96.23%、3.16%;严重AEFI、非严重AEFI报告发生率分别为0.14/10万剂、21.86/10万剂。各市(州)均有AEFI报告(仅2021年鄂州市为零报告),报告总例数居前3位的分别是荆州市、宜昌市和襄阳市。报告的AEFI中,男、女性别比为1.02∶1;2~6岁儿童占47.44%;第2、3季度报告例数较多,占比分别为35.79%、32.63%。96.92%的AEFI个案接种后至发生AEFI时间间隔≤1 d。不同制作工艺类型狂犬病疫苗AEFI报告发生率差异有统计学意义(χ^(2)=238.92,P<0.01)。冻干狂犬病疫苗(Vero细胞)的AEFI报告发生率高于其他3种狂犬病疫苗。结论2019—2022年湖北省狂犬病疫苗AEFI报告发生率呈波动下降,报告的AEFI以一般反应为主,非严重AEFI为罕见,严重AEFI为十分罕见,安全性良好。
文摘Objective:Analyze the relationship between inoculating one case of the COVID-19 inactivated vaccine(Vero cell)and immune thrombocytopenic purpura to provide a reference for the standardized handling of adverse events following immunization.Methods:According to the"National Monitoring Program for Suspected Adverse Reactions to Vaccinations,"an on-site investigation,data collection and analysis,expert group diagnosis,and medical association assessment were conducted on a case of immune thrombocytopenic purpura in District A of Chongqing after vaccination with the inactivated COVID-19 vaccine.The assessment report was delivered to the three relevant parties,the case was reviewed,and the experience was summarized.Results:The investigation and diagnosis by the district-level vaccination abnormal reaction expert group concluded that the disease that occurred after vaccination with the COVID-19 inactivated vaccine was secondary immune thrombocytopenic purpura,an abnormal reaction to the vaccination.The medical damage was classified as Level II Grade B.The vaccine production enterprise raised objections to this conclusion.After re-assessment by the municipal-level medical association,the conclusion was consistent with that of the district-level medical association.The vaccine production enterprise did not raise any further objections.Conclusion:Through active collaboration among district and municipal-level medical associations,disease control institutions,and vaccination units,the recipients have been promptly and effectively treated,providing financial support for their subsequent treatment and safeguarding their rights.The investigation and disposal procedures for adverse events following immunization in Chongqing are clear,and the mechanism is sound.It is necessary to continue strengthening the monitoring of adverse events following immunization according to the existing plan and to ensure timely and standardized handling.Simultaneously,it is crucial to strengthen vaccine management and vaccination management.
文摘目的分析深圳市南山区2005—2022年疑似预防接种异常反应(adverse events following immunization,AEFI)发生的流行病学特征,评价AEFI监测工作开展运转情况,评估疫苗的安全性。方法通过疑似预防接种异常反应信息管理系统收集整理深圳市南山区2005—2022年监测个案数据,采用描述性方法进行流行病学分析。结果2005—2022年深圳市南山区共报告疑似预防接种异常反应病例1748例,报告发生率为9.20/10万剂。其中一般反应1411例(80.72%)、异常反应277例(15.85%)、偶合症60例(3.43%)。其中≤1岁635例占36.33%,男女性别比为1.33∶1,5月份(213例,占12.19%)报告病例最多。结论深圳市南山区疑似预防接种异常反应监测系统运转良好,但需加强接种单位相关工作人员业务培训、督导,提高监测敏感性。
文摘目的分析铜陵市疑似预防接种异常反应(adverse events following immunization,AEFI)的分布情况,评价AEFI监测工作开展情况,为预防接种的安全实施提供依据。方法通过中国疾病预防控制信息系统国家免疫规划信息系统收集2017—2021年铜陵市报告的AEFI个案数据,采用描述流行病学方法对AEFI个案发生的时间和人群特征以及不同疫苗的AEFI发生情况等进行分析。结果2017—2021年铜陵市共接种疫苗1711172剂次,报告AEFI个案937例,年均报告发生率为54.76/10万剂次;其中一般反应810例(占86.45%),异常反应125例(占13.34%),偶合症2例(占0.21%)。AEFI个案报告主要集中在3—8月(708例,占75.56%)。男女报告个案数分别为492例和445例,性别比为1.11:1;年龄分布上以2岁以下婴幼儿为主(696例,占74.28%)。报告发生率居前三位的疫苗分别为冻干流感减毒活疫苗(鼻喷)(250.94/10万剂次)、DTap-Hib四联疫苗(219.22/10万剂次)、13价肺炎疫苗(170.16/10万剂次)。75.35%的AEFI发生在接种后24 h内,所有个案均已好转或痊愈。结论铜陵市疫苗安全性总体较好,2岁以下婴幼儿是AEFI发生的重点人群。
文摘Objective:To compare the reporting pattern of hearing loss and tinnitus across different vaccines brands used in Malaysia(BNT162b2,CoronaVac,ChAdOx1,Ad5.CoV2-S and BBIBP-CorV).Methods:This retrospective study included all reports of hearing loss and tinnitus occurring after COVID-19 vaccination that were received in the national pharmacovigilance database,QUEST,from February 24,2021 through July 31,2022.Reports given causality consistent or indeterminate were included.Results:There were 21 cases of hearing loss,with overall reporting rate of 0.29 cases per million doses.The rate was similar across BNT162b2,CoronaVac and ChAdOx1.For tinnitus,35 cases were reported,with the overall reporting rate of 0.49 cases per million doses,and the highest rate was reported for ChAdOx1.For both events,most cases aged 30 to 49 years.No gender disparity was observed.Both events were mainly reported to have occurred after the primary doses,with a median time-to-onset of two days.There were no statistically significant differences in the reporting patterns for both events across BNT162b2,CoronaVac and ChAdOx1 by age group,gender,race,and dose number.Conclusions:Despite the low reporting rates and insufficient evidence to confirm its relationship,hearing loss and tinnitus following vaccinations should not be ignored due to its disabling potential and impact on one’s quality of life.Continual reporting is encouraged for better signal characterization in the future.
